| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | GMP, ISO 9001, USP, BP |
| State: | Powder |
| Purity: | >98% |
| Product Name: | Finasteride |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
Hair Loss Treatment CAS 98319-26-7 Minoxidil Dutasteride Finasteride
| Product name | Finasteride |
| Cas | 98319-26-7 |
| Brand | Biohorlden |
| Appearance | White Powder |
| Specification | 99% |
| Type | Raw Materials |
| Package | 1Kg/25Kg/Drum or As per your request |
| Storage | Store in cool and dry places ,keep away from strong light |
| Shelf life | 2 years when properly stored |
Finasterideis an antiandrogen which acts by inhibiting type II 5alpha reductase.It is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses. It is also indicated for use in combination with doxazosin therapy to reduce the risk for symptomatic progression of BPH. Additionally, it is registered in many countries for androgenetic alopecia (male-pattern baldness).
Finasteride was approved initially in 1992, a treatment for prostate enlargement, but the sponsor had studied 1 mg of finasteride and demonstrated hair growth in male pattern hair loss. On December 22, 1997, the FDA approved finasteride to treat male pattern hair loss.
| Item | Specification | Test Results |
| Characteristics | White or off-white crystalline powder | Complies |
| Soluility | Freely soluble in methylene chloride and in alcohol;practically insoluble in water | Complies |
| Identification | IR-Spectrum HPLC |
Complies |
| Specific Rotation | -50°~-60° | -58° |
| Water | ≤0.3% | 0.1% |
| Residue on Ignition | ≤0.1% | 0.01% |
| Heavy Metals | ≤10 | <10 |
| Relative Material | Major≤0.5 Total≤1.0 |
0.3 0.5 |
| Residual Solvent | Complies | Complies |
| Assay | 98.5%~101.0% | 99.2% |
| Conclusion | The result conforms the standard | |
1) Used for treatment of hair loss;
2) For the treatment of benign prostatic hyperplasia, enlarged prostate shrink, improve urinary flow and improvement of benign prostatic hyperplasia caused symptoms.
Benign prostatic hyperplasia
Physicians use finasteride for the treatment of BPH, informally known as an enlarged prostate. The FDA-approved dose is 5 mg once a day. Six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits reverse within about -8 months. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.
Male pattern baldness
Finasteride is used to treat male pattern hair loss (androgenetic alopecia) in men only. Treatment provides about 30% improvement in hair loss after six months of treatment, and effectiveness only persists as long as the drug is taken.
Off-label uses
Finasteride is sometimes used in hormone replacement therapy for male-to-female transsexuals in combination with a form of estrogen due to its antiandrogen properties. However, little clinical research of finasteride use for this purpose has been conducted and evidence of efficacy is limited.
Xi'an Biohorlden Industry&Trade Co.,Ltd is a national key high-tech enterprise,which mainly specializes in the R&D, operation and production of pharmaceuticals,and intermediates.Our company is situated in E&T development zone,xi'an city shaanxi,it is easy of access. Our company has independent R&D center,raw material synthesis workshop, has advanced quality instruments and equipmentm,several product patents there are 15 experts in our research team.We insist in innovation and produce high quality products.
1.Are you a manufacturer or trade company?
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}